Victoria N. Parikh

Stanford University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (7)

Cardiac fibrosis is a central pathological process in heart failure, yet the molecular mechanisms governing its spatial organization remain poorly defined. We developed an artificial intelligence (AI)-based phenotyping approach to decode the spatial organization of cardiac fibrosis from routine cardiac magnetic resonance imaging (MRI). We applied convolutional variational autoencoders (VAEs) and distributional metrics to native T1 maps from 50,239 UK Biobank participants. VAE-derived features predicted mortality with greater precision than standard T1 measures (C-index 0.614 vs. 0.547; likelihood ratio p = 2.9×10 -3 ), identifying spatial fibrosis patterns as independent prognostic indicators. Through genome-wide association studies, we identified genetic loci underlying T1 distribution metrics, implicating oxidative stress pathways (SOD2, GSS) and calcium signaling (CAMK2D, CALU). Pathway enrichment revealed distinct biological processes: T1 distributions reflected metabolic and coagulation activity, while spatial VAE dimensions reflected extracellular matrix organization and complement regulation. Mendelian randomization identified cathepsin S (CTSS) and extracellular matrix protein 1 (ECM1) as causal mediators with near-certain colocalization evidence (PP.H4>0.88), validated in an independent Icelandic cohort (n=35,559). FKBPL demonstrated causal effects on both T1 distributional and spatial features. Published preclinical studies show CTSS inhibition reduces collagen deposition and ventricular stiffening, ECM1 stabilizes extracellular matrix and prevents fibrosis, and FKBPL peptides attenuate fibroblast activation. These findings highlight tractable pathways for therapeutic modulation of myocardial fibrosis.

Year:

2025

Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.

Year:

2025

Extrachromosomal-circular DNA (eccDNA) are circular-DNA elements that are implicated in cellular processes such as genomic diversification and instability, along with other genomic mechanisms. However, their structure and chromatinization state is poorly understood. Here we identified a 358-bp circular micro-eccDNA molecule derived from the human Titin gene, which was selected for this study based on its size and sequence characteristics, and used atomistic molecular dynamics simulations to study its interaction with nucleosomes and corresponding topological state. We show the presence or absence of bound nucleosomes provides a topological switch between intact and denatured DNA.

Year:

2025

Background An estimated 1 in 500 people live with hypertrophic cardiomyopathy (HCM), a disease for which genetic diagnosis can identify family members at risk, and increasingly guide therapy. Mutations in the myosin binding protein C3 ( MYBPC3 ) gene account for a significant proportion of HCM cases. However, many of these variants are classified as variants of uncertain significance (VUS), complicating clinical decision-making. Scalable methods for variant interpretation in disease-specific cell types are crucial for understanding variant impact and uncovering disease mechanisms. Methods We developed a scaled multidimensional mapping strategy to evaluate the functional impact of variants across a critical domain of MYBPC3. We incorporate saturation base editing at the native MYBPC3 locus, a long-read RNA sequencing-enabled assay of variant splice effects, and measurements of HCM-relevant phenotypes, including MYBPC3 abundance, hypertrophic signaling, and ubiquitin-proteasome function in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Results Our multidimensional mapping strategy enabled high-resolution functional analysis of MYBPC3 variants in iPSC-CMs. Targeted transient base editing generated a comprehensive variant library at the native locus, capturing diverse variant effects on cellular HCM-relevant phenotypes. Our massively parallel splicing assay identified novel splice-disrupting variants. Integration of functional assays revealed that decreased MYBPC3 abundance is a key driver of HCM-related phenotypes. In parallel, downregulation of protein degradation was observed as a compensatory response to MYBPC3 loss of function, and novel disease mechanisms were identified for missense variants near a critical binding domain, underscoring their contribution to pathogenesis. Bayesian estimates of variant effects enable the reclassification of clinical variants. Conclusions This work provides a platform for extending genome engineering in iPSCs to multiplexed assays of variant effects across diverse disease-relevant cellular phenotypes, enhancing the understanding of variant pathogenicity and uncovering novel biological mechanisms that could inform therapeutic strategies.

Year:

2025

BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction <35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome. RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient <50 mm Hg at 1 year. After 6.8 years (range, 3.4–9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1–1.3]; P <0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1–1.2] per 5-year increase; P <0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1–1.8]; P <0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction. CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.

Year:

2024

Background: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ~1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. Here we report work by the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel (HCVD-GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes. Methods: The ClinGen systematic gene curation framework was used to re-classify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2-3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD-GCEP composed of 29 individuals from 21 institutions across 6 countries. Results: Thirty-one genes were re-curated and an additional 5 new potential HCM-associated genes were curated. Among the re-curated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, two genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semi-dominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive). Conclusions: We report 29 genes with definitive, strong or moderate evidence of causation for HCM or isolated LVH, including sarcomere, sarcomere-associated and syndromic conditions.

Year:

2024

Year:

2023

Collaborators (61)

Sharlene Day

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Arthur A M Wilde

University of Amsterdam

NETHERLANDS
View details

Courtney Thaxton

Associate Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Nisha Gilotra

Assistant Professor of Medicine

Johns Hopkins University School of Medicine

UNITED STATES
View details

Roddy Walsh

Researcher/Lecturer

City, University of London

UNITED KINGDOM
View details

Anjali T. Owens

Assistant Professor, Clinician-Educator

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Firat Duru

-

SWITZERLAND
View details

Kristina Haugaa

Professor

University of Oslo

NORWAY
View details

A.s Amin

Cardiologist

Amsterdam University Medical Centers

NETHERLANDS
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Francois Haddad

Associate Professor of Cardiovascular Medicine

Stanford University

UNITED STATES
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

J. Peter van Tintelen

Head Department; clinical geneticist

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Elizabeth M. McNally

Director

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Matthew Taylor

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Lia Crotti

Director of the Cardiological Rehabilitation Unit, San Luca Hospital

IRCCS Istituto Auxologico Italiano

ITALY
View details

Sing-Chien Yap

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Michela Casella

Researcher

Università Politecnica delle Marche

ITALY
View details

Sarah Harris

Professor of Biological and Materials Physics

University of Sheffield

UNITED KINGDOM
View details

Elizabeth Jordan

Ohio State University

UNITED STATES
View details

Michelle Michels

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Qianru Wang

Associate Professor (non-tenured)

Shanghai Jiao Tong University

CHINA
View details

Dan M Roden

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

John Stendahl

Yale University

UNITED STATES
View details

R Foo

Professor

National University of Singapore (NUS)

SINGAPORE
View details

Andrew Glazer

Assistant Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Petros Syrris

University College London

UNITED KINGDOM
View details

B. Callewaert

Associate Professor

Ghent University

BELGIUM
View details

Iacopo Olivotto

University of Florence

ITALY
View details

James Ware

Professor

Imperial College London

UNITED KINGDOM
View details

Marco Merlo

University of Trieste

ITALY
View details

Marina Cerrone

Research Assistant Professor of Medicine

NYU School of Medicine

UNITED STATES
View details

Jodie Ingles

Head, Ingles Lab

Garvan Institute of Medical Research

AUSTRALIA
View details

Matthew Wheeler

Associate Professor

Stanford University

UNITED STATES
View details

Thomas Ryan

Associate Professor - Clinical

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Andrew Z Fire

Professor

Stanford University School of Medicine

UNITED STATES
View details

Gianfranco Sinagra

University of Trieste

ITALY
View details

Laura Muiño Mosquera

Staf

Ghent University Hospital

BELGIUM
View details

Barbara Bauce

Associate Professor

University of Padova

ITALY
View details

Hugh Calkins

Johns Hopkins University School of Medicine

UNITED STATES
View details

Cynthia James

Associate Professor

Johns Hopkins University

UNITED STATES
View details

Nosheen Reza

University of Pennsylvania

UNITED STATES
View details

Andrew Landstrom

Professor

Duke University School of Medicine

UNITED STATES
View details

Euan A. Ashley

Professor

Stanford University School of Medicine

UNITED STATES
View details

Joseph Rossano

Children's Hospital of Philadelphia

UNITED STATES
View details

Thomas Bishop

associate professor

Louisiana Tech University

UNITED STATES
View details

cristina basso

Professore Ordinario di Anatomia Patologica

University of Padova

ITALY
View details

Kalliopi Pilichou

Associate Professor

University of Padua

ITALY
View details

Ardan M. Saguner

-

SWITZERLAND
View details

Stephen Levene

Professor

University of Texas at Dallas

UNITED STATES
View details

Luisa Mestroni

Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Juan Gimeno Blanes

Associate Professor

Universidad de Murcia

SPAIN
View details

Marco Schiavone

Clinical Scientist

Centro Cardiologico Monzino

ITALY
View details

Richard D. Bagnall

University of Sydney

AUSTRALIA
View details

Rachel Lampert

Yale University School of Medicine

UNITED STATES
View details

Ashwin S. Nathan

-

UNITED STATES
View details

Giovanni Peretto

Vita-Salute San Raffaele University

ITALY
View details

Perry Elliott

University College London

UNITED KINGDOM
View details

David Staudt

Stanford University

UNITED STATES
View details

Calum MacRae

Professor

Harvard University

UNITED STATES
View details